EyePoint set for record drop after experimental eye drug misses late-stage study goal
EYPT•Late-stage Duravyu study misses main goal
Shares of EyePoint (EYPT.O) tumble 71% to $4.17, on track for their biggest one-day drop on record and lowest level since April 2025.
The drug developer says experimental eye drug Duravyu missed the main goal of a late-stage trial against Regeneron's blockbuster eye drug Eylea in patients with wet age-related macular degeneration, a leading cause of vision loss.
It adds that an analysis excluding nine patients whose vision loss was unrelated to wet AMD showed Duravyu performed similarly to Eylea.
Duravyu reduced treatment burden by 42% versus Eylea, or about two fewer injections through Week 56 - EYPT.
The company says 54% of patients were supplement-free through Week 56, and 79% received zero or one supplemental injection.
EyePoint sees data from a second late-stage wet AMD study in Q4 2026, and plans a potential FDA filing in H1 2027.
Including the session's move, the stock is down about 77% year to date.
